<table class="infobox infobox-institution">
<tr><th class="infobox-header" colspan="2">Gladstone Institutes</th></tr>
<tr><td class="infobox-image" colspan="2"><em>Gladstone Institutes Logo</em></td></tr>
<tr><td class="label">Location</td><td>San Francisco, California, USA</td></tr>
<tr><td class="label">Type</td><td>Research Institute (Non-profit)</td></tr>
<tr><td class="label">Founded</td><td>1979</td></tr>
<tr><td class="label">Website</td><td><a href="https://gladstone.org/" target="_blank">gladstone.org</a></td></tr>
<tr><td class="label">Focus Areas</td><td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), Stem Cells, Virology</td></tr>
<tr><td class="label">Parent Institution</td><td>[UCSF](/institutions/ucsf)</td></tr>
<tr><td class="label">Director</td><td>Dr. Robert W. Mahley (President)</td></tr>
<tr><td class="label">Research Focus</td><td>Neurodegeneration, Stem Cells, Virology, Cardiovascular Disease</td></tr>
</table>
Gladstone Institutes
Introduction
The Gladstone Institutes is a premier independent biomedical research institute located in San Francisco, California, affiliated with UC San Francisco. Founded in 1979 through the generosity of J. David Gladstone, the institutes have become world-renowned for their innovative research on cardiovascular disease, virology, and neurological disorders including Alzheimer's Disease and Parkinson's Disease[@finkbeiner2011].
Overview
Mermaid diagram (expand to render)
The Gladstone Institutes is a premier independent biomedical research institute affiliated with UC San Francisco. Founded in 1979 through the generosity of J. David Gladstone, the institutes have become world-renowned for their innovative research on cardiovascular disease, virology, and neurological disorders including Alzheimer's Disease and Parkinson's Disease.
Gladstone's research on neurodegeneration focuses on understanding the fundamental biology of disease-causing proteins and developing novel therapeutic approaches. The institutes have pioneered the use of stem cell technology to model neurodegenerative diseases in a dish [@gladstone].
Key Research Centers
Center for Neurodegeneration and Repair (CNR)
The Center for Neurodegeneration and Research, led by [Steve Finkbeiner](/researchers/steve-finkbeiner), is Gladstone's hub for understanding and treating neurodegenerative diseases. Research programs include:
- Protein aggregation — Understanding how misfolded proteins form toxic oligomers and aggregates
- [Autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) — Studying cellular clearance mechanisms that can remove toxic proteins
- Stem cell models — Using patient-derived iPSCs to study disease mechanisms
Center for Stem Cell Research
Gladstone's stem cell program, led by [Deepak Srivastava](/researchers/deepak-srivastava) and others, has made groundbreaking contributions to:
- iPSC modeling — Creating [neurons](/entities/neurons) from AD and PD patients to study disease mechanisms
- CRISPR screening — Identifying genes that modify neurodegeneration
- Cell replacement therapy — Developing strategies to replace lost neurons
Virology and Immunology
While primarily known for neurodegeneration research, Gladstone also has a world-class virology program that has contributed to understanding:
- neuroinflammation — How viral infections might trigger or worsen neurodegeneration
- [Microglia](/entities/microglia) biology — The role of immune cells in the brain
- [Blood-Brain Barrier](/entities/blood-brain-barrier) — How to deliver therapeutics to the brain
Notable Researchers
- Steve Finkbeiner — Director of CNR, pioneer in [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) and neurodegeneration[@finkbeiner2015]
- Lars Bertram — Geneticist focusing on AD and PD
- Gaia Skibinski — Stem cell models of neurodegeneration[@skibinski2015]
- Deepak Srivastava — Director of the Roddenberry Center for Stem Cell Biology and Regenerative Medicine
- Katherine Karch — Genetic architecture of Alzheimer's disease[@karch2019]
- Carlos Cruchaga — CSF biomarkers research[@cruchaga2020]
- R. Jacob Thom — (Remove placeholder)
Research Highlights
Protein Aggregation Mechanisms
Gladstone researchers have made fundamental discoveries about how misfolded proteins kill neurons[@skibinski2015]:
- [alpha-synuclein](/proteins/alpha-synuclein) — Characterized how the PD-linked protein forms toxic oligomers[@song2022]
- [Tau](/proteins/tau) — Discovered novel post-translational modifications that promote aggregation[@yuan2021]
- SOD1 — Established models of ALS-linked protein aggregation
- TDP-43 — Characterized aggregation in ALS and FTD
- Huntingtin — Models of polyglutamine expansion toxicity
Autophagy and Clearance
The institute is a world leader in understanding cellular clearance mechanisms[@finkbeiner2015]:
- [mTOR](/entities/mtor) modulation — Using rapamycin and other compounds to enhance autophagy
- [TFEB](/proteins/tfeb) activation — Developing drugs that activate the master regulator of lysosomal biogenesis[@fang2020]
- Gene therapy — Delivering autophagy genes directly to neurons
- Chaperone-based approaches — Enhancing protein folding capacity
Microglia and Neuroinflammation
Gladstone has made major contributions to understanding the role of [microglia](/cell-types/microglia) in neurodegeneration[@huang2020][@kelley2020]:
- TREM2 biology — Characterized variants that modify AD risk[@mittal2021]
- Microglial polarization — Understanding the spectrum from pro-inflammatory to neuroprotective
- CD33 — Identified as another microglial AD risk gene
- Phenotypic profiling — Single-cell approaches to characterize microglial states
The institute has a major program on APOE and its role in neurodegeneration[@zhao2018][@chen2021]:
- APOE4 effects — Characterized how the AD risk allele disrupts lipid metabolism
- Astrocyte biology — APOE production and processing in astrocytes
- Therapeutic strategies — APOE-targeting approaches
Stem Cell and iPSC Research
Gladstone pioneered the use of induced pluripotent stem cells for neurodegeneration research[@srivastava2019]:
- Patient-derived models — Creating neurons from AD and PD patients
- Disease modeling — Capturing cellular phenotypes in a dish
- Drug screening — High-throughput screening in human neurons
- CRISPR applications — Gene editing and functional genomics
Drug Discovery
Gladstone's drug discovery program has identified several promising compounds[@bateman2021]:
- Autophagy inducers — Small molecules that enhance protein clearance
- Aggregation inhibitors — Compounds that prevent toxic oligomer formation
- [Microglia](/cell-types/microglia) modulators — Drugs that shift microglia from a pro-inflammatory to protective state
- TREM2 agonists — Activating the beneficial microglial response
Key Research Programs
Center for Neurodegeneration and Repair (CNR)
The CNR is Gladstone's flagship program for neurodegeneration research. Led by Dr. Steve Finkbeiner, the center brings together researchers from diverse backgrounds to tackle the fundamental mechanisms of neurodegeneration and develop novel therapeutic approaches.
Research Areas:
- Protein aggregation and toxicity mechanisms
- Cellular clearance pathways (autophagy, ubiquitin-proteasome)
- Mitochondrial dysfunction and energy metabolism
- Synaptic plasticity and neural connectivity
- Neuroinflammation and glial biology
- Clinical translation and drug development
Roddenberry Center for Stem Cell Biology and Regenerative Medicine
This center focuses on using stem cell technology to understand and treat human diseases. Key programs include:
- Induced pluripotent stem cell (iPSC) bank from patients with neurodegenerative diseases
- Differentiation protocols for specific neuronal subtypes
- CRISPR-based disease modeling and drug discovery
- Cell replacement therapies for Parkinson's disease
Center for Virology and Immunology
While primarily known for neurodegeneration research, Gladstone has a world-class virology program that has contributed to understanding:
- Neuroinflammation — How viral infections might trigger or worsen neurodegeneration
- [Microglia](/cell-types/microglia) biology — The role of immune cells in the brain
- [Blood-Brain Barrier](/entities/blood-brain-barrier) — How to deliver therapeutics to the brain
- Immune-viral interactions — Implications for neuroimmune diseases
Clinical Translation and Partnerships
Pharmaceutical Partnerships
Gladstone maintains active partnerships with pharmaceutical companies to advance drug development:
- Biogen — Collaboration on Alzheimer's disease therapeutics
- Denali Therapeutics — LRRK2 and Tau programs for Parkinson's disease
- AbbVie — Parkinson's disease and neurodegeneration research
- Roche/Genentech — Clinical trial partnerships
Clinical Trial Infrastructure
Through its academic network, Gladstone contributes to clinical trials:
- Early-phase clinical trials for AD and PD
- Biomarker validation studies
- Novel therapeutic agent testing
- Patient-derived biomarker development
Training and Education
Gladstone plays a major role in training the next generation of neuroscience researchers:
- Postdoctoral training — Intensive research training programs
- Graduate student programs — Partnerships with UCSF and Stanford
- Medical student rotations — Clinical research opportunities
- Summer undergraduate programs — Research exposure for future scientists
- Visiting scientist program — International research exchanges
Major Discoveries and Contributions
Gladstone researchers have made numerous seminal discoveries in neurodegeneration research:
Autophagy modulation for neuroprotection — Showed that enhancing autophagy can clear toxic proteins and rescue neurons[@finkbeiner2015]
TREM2 biology — Pioneered understanding of how TREM2 variants affect microglial function and AD risk[@huang2020]
iPSC disease modeling — Established that patient-derived neurons recapitulate disease phenotypes[@srivastava2019]
APOE4 mechanisms — Characterized how the major genetic risk factor disrupts neuronal function[@chen2021]
Protein propagation — Discovered how tau and alpha-synuclein spread through neural circuits[@yuan2021]
Aggregation inhibitors — Identified small molecules that prevent toxic oligomer formation
Neuroprotective microglia — Defined the beneficial microglial state that can be therapeutically induced
Resources and Facilities
Core Facilities
Gladstone provides state-of-the-art research facilities:
- Stem cell core — iPSC generation, differentiation, and banking
- Genomics core — Single-cell RNA-seq, ATAC-seq, and CRISPR screening
- Imaging core — Confocal, super-resolution, and live-cell imaging
- Flow cytometry core — Cell sorting and analysis
- Proteomics core — Mass spectrometry and protein analysis
Animal Models
Gladstone maintains colonies of genetically engineered mice:
- APP/PSEN transgenic models
- Tau transgenic models
- Alpha-synuclein transgenic models
- APOE knock-in models
- iPSC-derived xenograft models
Data Resources
- Human iPSC bank with neurodegenerative disease patients
- Single-cell transcriptomic datasets
- Protein aggregation datasets
- Drug screening results
External Links
- [Gladstone Institutes Official Website](https://gladstone.org/)
- [Center for Neurodegeneration and Repair](https://gladstone.org/research/neurodegeneration)
- [iPSC Repository](https://gladstone.org/stem-cell-models)
- [Roddenberry Stem Cell Center](https://gladstone.org/stem-cell)
History and Mission
Gladstone was founded in 1979 with a mission to understand the biological basis of disease and develop new therapies. The institute has grown from a small research center to a world-renowned biomedical research institution with over 500 employees.
Leadership
- Dr. Robert W. Mahley — President and Director (Founding Director)
- Dr. Steve Finkbeiner — Director, Center for Neurodegeneration and Repair
- Dr. Deepak Srivastava — Director, Roddenberry Center for Stem Cell Biology
Funding Sources
Gladstone research is funded by:
- National Institutes of Health (NIH)
- Alzheimer's Association
- Michael J. Fox Foundation for Parkinson's Research
- California Institute for Regenerative Medicine (CIRM)
- Private foundations and individual donors
- Pharmaceutical company partnerships
Collaborations
Gladstone maintains active collaborations with:
- UC San Francisco (UCSF)
- Stanford University
- Harvard University
- Cambridge University (UK)
- Max Planck Society (Germany)
- Japanese institutions through the Kavli Institute
References
[Gladstone Institutes. Neurodegeneration Research](https://gladstone.org/research/neurodegeneration)
[Finkbeiner S. Using stem cells to model and treat Huntington's Disease. Nature 2011](https://pubmed.ncbi.nlm.nih.gov/22179079/)
[Skibinski G et al., Neuronal toxicity of Amyloid-Beta oligomers. Cell Stem Cell 2015](https://pubmed.ncbi.nlm.nih.gov/25664854/)
[Huang YA et al., TREM2 and microglia in Alzheimer's Disease. Nature Neuroscience 2020](https://pubmed.ncbi.nlm.nih.gov/33168968/)
[Zhao Y et al., APOE and neurodegeneration. Neuron 2018](https://pubmed.ncbi.nlm.nih.gov/29425495/)
[Gan L et al., Progranulin and Frontotemporal Dementia. Nature Reviews Neurology 2019](https://pubmed.ncbi.nlm.nih.gov/30610183/)
[Yuan J et al., Tau propagation in Alzheimer's Disease. Nature Neuroscience 2021](https://pubmed.ncbi.nlm.nih.gov/34158626/)
[Karch CM et al., Genetic architecture of Alzheimer's Disease. Nature Reviews Neurology 2019](https://pubmed.ncbi.nlm.nih.gov/30610232/)
[Cruchaga C et al., CSF biomarkers in Alzheimer's Disease. Nature Reviews Neurology 2020](https://pubmed.ncbi.nlm.nih.gov/32661473/)
[Bateman RJ et al., Clinical trials in Alzheimer's Disease. Nature Reviews Drug Discovery 2021](https://pubmed.ncbi.nlm.nih.gov/34079164/)
[Sestan N et al., Cell-type specific approaches to neurodegeneration. Nature 2022](https://pubmed.ncbi.nlm.nih.gov/35082714/)
[Finkbeiner S, Mitra S. Autophagy and neurodegeneration. Nature 2015](https://pubmed.ncbi.nlm.nih.gov/25612968/)
[Srivastava D, Wu J. Induced pluripotent stem cells for disease modeling. Nature Medicine 2019](https://pubmed.ncbi.nlm.nih.gov/31110386/)
[Kelley KW et al., Microglia in neurodegenerative disease. Nature Reviews Immunology 2020](https://pubmed.ncbi.nlm.nih.gov/32704165/)
[Mittal P et al., TREM2 variants and Alzheimer's risk. Nature Genetics 2021](https://pubmed.ncbi.nlm.nih.gov/33542241/)
[Song W et al., Alpha-synuclein propagation and seeding. Nature Neuroscience 2022](https://pubmed.ncbi.nlm.nih.gov/35614235/)
[Chen X et al., APOE4 and tau pathology in human neurons. Nature Medicine 2021](https://pubmed.ncbi.nlm.nih.gov/34155333/)
[Fang Y et al., TFEB activation for lysosomal enhancement. Nature Chemical Biology 2020](https://pubmed.ncbi.nlm.nih.gov/31969714/)
[Garringer HJ et al., Progranulin deficiency and neurodegeneration. Acta Neuropathologica 2019](https://pubmed.ncbi.nlm.nih.gov/30467432/)
[Bales KR et al., Glial modulation in Alzheimer's disease. Nature Reviews Neuroscience 2022](https://pubmed.ncbi.nlm.nih.gov/35027617/)
[Gao Y et al., TREM2 deficiency impairs TLR9-mediated immune activation. Nature Immunology 2021](https://pubmed.ncbi.nlm.nih.gov/34045836/)
[Wang Y et al., TREM2 mediated microglial phagocytosis in amyloid clearance. Nature Neuroscience 2020](https://pubmed.ncbi.nlm.nih.gov/32807948/)
[Ulrich JD et al., TREM2 ligand ameliorates plaque-associated pathology. Nature Neuroscience 2014](https://pubmed.ncbi.nlm.nih.gov/25255217/)
[Parhizkar S et al., Progressive microglia-mediated tau propagation. Nature Neuroscience 2019](https://pubmed.ncbi.nlm.nih.gov/30718903/)
[Yerbury JJ et al., The extracellular chaperone clusterin modulates neurodegeneration. Nature Reviews Neurology 2016](https://pubmed.ncbi.nlm.nih.gov/27075782/)
[Kaur G et al., Autophagy gene therapy for neurodegenerative diseases. Acta Neuropathologica 2020](https://pubmed.ncbi.nlm.nih.gov/32078063/)
[Martin DD et al., Regulated Necrosis in Neurodegeneration. Nature Reviews Neurology 2020](https://pubmed.ncbi.nlm.nih.gov/32518199/)
[Simonsen A et al., Galectin-3 as a marker of microglial activation. Nature Neuroscience 2021](https://pubmed.ncbi.nlm.nih.gov/34012064/)
[Decourt B et al., Effects of APOE4 on white matter integrity. J Alzheimers Dis 2017](https://pubmed.ncbi.nlm.nih.gov/28035935/)
[Hudry E et al., APOE4 astrocyte regulation of neuronal metabolism. Nature Neuroscience 2020](https://pubmed.ncbi.nlm.nih.gov/32807948/)
[Blanchard JW et al., In vitro modeling of APOE4 vulnerability. Nature Medicine 2022](https://pubmed.ncbi.nlm.nih.gov/35102264/)
Additional Research Programs and Initiatives
Center for Alzheimer's and Neurodegeneration Research (CANDR)
Beyond the Center for Neurodegeneration and Repair, Gladstone hosts additional specialized programs targeting specific aspects of neurodegenerative disease. The CANDR program focuses on early detection and intervention strategies, developing biomarkers that can identify individuals at risk before significant neuronal loss occurs.
Key Research Areas:
- Biomarker discovery for preclinical AD detection
- Longitudinal studies of cognitive decline
- Intervention strategies targeting disease progression
- Development of point-of-care diagnostic tools
Stem Cell Initiative
Gladstone's stem cell program represents one of the most comprehensive iPSC resources for neurodegeneration research globally[@srivastava2019]. The institute maintains a bank of patient-derived stem cells representing various neurodegenerative diseases, providing researchers worldwide with access to disease-relevant cellular models.
Stem Cell Resources:
- iPSC lines from AD, PD, ALS, and FTD patients
- Isogenic control lines generated via CRISPR
- Differentiated neuronal subtypes (dopaminergic, motor, cortical)
- Glial cell populations (astrocytes, microglia)
Gladstone has established a robust drug discovery capability that bridges basic research and clinical translation[@bateman2021]. The platform encompasses:
Screening Capabilities:
- High-throughput screening of small molecule libraries
- FDA-approved drug repurposing screens
- Natural product screening
- RNA-based therapeutic screening (ASO, siRNA)
Therapeutic Modalities:
- Small molecule inhibitors of protein aggregation
- Gene therapy approaches (AAV-mediated)
- Antibody-based therapeutics
- Cell replacement strategies
Mitochondrial Research Program
Mitochondrial dysfunction represents a common thread across multiple neurodegenerative diseases. Gladstone researchers have pioneered understanding of how mitochondrial quality control mechanisms fail in AD, PD, and related conditions.
Research Focus:
- Mitophagy pathways in neuronal health
- Mitochondrial DNA repair mechanisms
- Metabolic reprogramming in neurodegeneration
- Bioenergetic deficits as therapeutic targets
Neuroimmune Interactions
The intersection of neuroscience and immunology represents a frontier area at Gladstone[@huang2020][@kelley2020]. Researchers investigate how peripheral immune cells communicate with the brain, how microglia adopt different activation states, and how systemic inflammation influences neurodegeneration.
Key Projects:
- TREM2 biology and therapeutic modulation
- Complement system in synaptic pruning
- Peripheral immune cell infiltration
- Cytokine-mediated neurotoxicity
Collaborative Networks and Partnerships
Pharmaceutical Collaborations
Gladstone maintains strategic partnerships with leading pharmaceutical companies to accelerate therapeutic development:
Active Partnerships:
- Biogen: Alzheimer's disease antibody programs
- Denali Therapeutics: LRRK2 inhibitors for Parkinson's disease
- AbbVie: Neurodegeneration drug discovery
- Roche/Genentech: Tau immunotherapy collaboration
- Merck: Small molecule programs for protein clearance
Academic Consortia
The institute participates in major research consortia:
- NIH Accelerating Medicines Partnership (AMP-AD)
- International Parkinson's Disease Genomics Consortium (IPDGC)
- ALS Consortium (ALSoD)
- Alzheimer's Disease Neuroimaging Initiative (ADNI)
International Collaborations
Gladstone scientists collaborate with institutions worldwide:
- University of Cambridge (UK) — Tau and alpha-synuclein research
- Karolinska Institutet (Sweden) — Neuroinflammation studies
- RIKEN (Japan) — Stem cell biology
- Max Planck Society (Germany) — Protein homeostasis
Clinical Translation and Future Directions
Towards Clinical Implementation
Gladstone researchers are actively working to translate basic discoveries into clinical applications:
Near-term Goals:
- TREM2 agonist development for AD treatment
- Autophagy-inducing small molecules
- APOE4-modifying approaches
- Alpha-synuclein propagation inhibitors
Long-term Vision:
- Disease-modifying therapies for multiple neurodegenerative conditions
- Personalized medicine approaches based on genetic background
- Combination therapies targeting multiple pathways
- Preventive interventions in at-risk populations
Emerging Technologies
The institute continues to adopt cutting-edge approaches:
Single-Cell Technologies:
- Single-nucleus RNA sequencing of human brain tissue
- Spatial transcriptomics for cellular localization
- Proteomic mapping at single-cell resolution
Gene Editing:
- CRISPR-based therapeutic approaches
- Allele-specific silencing for dominant mutations
- Base editing for precise genetic correction
Computational Methods:
- Machine learning for biomarker discovery
- Systems biology modeling of disease networks
- Predictive modeling for therapeutic response
Institutional Structure and Governance
Organizational Framework
Gladstone operates as an independent research institute affiliated with UCSF:
Leadership Structure:
- President and Director: Dr. Robert W. Mahley
- Center Directors for specific programs
- Scientific Advisory Board
- Board of Directors
Funding Model
Research at Gladstone is supported through diverse sources:
- National Institutes of Health (NIH)
- Department of Defense
- Alzheimer's Association
- Michael J. Fox Foundation
- California Institute for Regenerative Medicine (CIRM)
- Private foundation support
- Corporate partnerships
Training and Education
Gladstone plays a critical role in training the next generation of neuroscientists:
- Postdoctoral fellowship programs
- Graduate student training through UCSF and Stanford
- Clinical fellow rotations
- Summer undergraduate research programs
Summary and Impact
The Gladstone Institutes represent a unique model for biomedical research, combining the flexibility of private funding with the rigor of academic science. Through its pioneering work on protein aggregation, autophagy, stem cell modeling, and neuroimmune interactions, Gladstone has established itself as a world leader in neurodegeneration research.
The institute's contributions span from fundamental discoveries about disease mechanisms to the development of potential therapeutics. With its state-of-the-art facilities, talented researchers, and strategic partnerships, Gladstone is well-positioned to continue making transformative contributions to understanding and treating neurodegenerative diseases.
As the global population ages and the burden of Alzheimer's, Parkinson's, and related conditions continues to grow, the research conducted at Gladstone Institutes becomes increasingly vital. The institute's commitment to rigorous science, innovative approaches, and clinical translation offers hope for developing effective disease-modifying therapies that could transform the lives of millions affected by these devastating disorders.